Microbot Medical opened lower at $1.10, compared with its previous close of $1.11. In the last trading session, the stock traded between $1.03 and $1.10. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Microbot Medical is now worth
$ 14.85
Resulting in a loss of
$ 85.15 (85.15%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.08 (-6.76%)
Day High
$1.10
Day Low
$1.03
Day Open
$1.10
Prev Close
$1.11
Volume
9,36,200
1W Return
-9.61%
1M Return
-0.96%
3M Return
-38.58%
6M Return
-52.74%
1Y Return
-50.48%
Market Cap ($ Mn)
70
PE Ratio
-
PB Ratio
1.44
PEG Ratio
-
ROE
-30.06%
ROCE
-32.80%
EPS (TTM)
$-0.08
1 Week
-9.61%
1 Month
-0.96%
3 Months
-38.58%
6 Months
-52.74%
9 Months
-48.25%
Microbot Medical secures new patents in US, Japan, China and Canada
Microbot Medical secured new patents in US, Japan, China, and Canada. Total issued patents now stand at 44 globally. Pending patent applications total 49 across multiple regions. Expansion supports LIBERTY system commercialization and CE Mark pursuit.
23 days agoMicrobot Medical targets 12 sales territories by year-end
Microbot Medical plans to reach 12 sales territories by year-end. Secured first customer in California and expanded in North Carolina. Hired three Area Sales Managers and one Regional Sales Director. Expects positive gross margins in 2027 via manufacturing efficiencies. CE mark approval expected in late Q4 2026 or early Q1 2027.
1mo agoMicrobot Medical Q2 Results: Sales miss by 29%, EPS in line
Microbot Medical met Q2 EPS estimates at $(0.08), a 20% improvement YoY from $(0.10). However, sales of $241,000 missed the $340,000 estimate by 29.12%, raising concerns about revenue growth despite stable per-share losses.
3mo agoMicrobot Medical reports 100% revenue growth in Q2
Microbot Medical Inc. achieved over 100% revenue growth in Q2 2026 compared to Q1 2026, driven by new customers for its LIBERTY Endovascular Robotic System. The company reported this progress for the period ended June 30, 2026.
4mo agoMicrobot Medical partners with Lovell to serve federal healthcare
Microbot Medical Inc. has partnered with Lovell Government Services to distribute its LIBERTY Endovascular Robotic System to federal healthcare systems, including the VHA, MHS, and IHS. The LIBERTY System will be added to Lovell's Federal Supply Schedule contract in Q3 2026, accessible via platforms like GSA Advantage and ECAT.
4mo agoMicrobot Medical expands LIBERTY System adoption to Michigan
Microbot Medical Inc. announced the first adoption of its LIBERTY Endovascular Robotic System by a major health system in Michigan, expanding its presence into the Midwest U.S. This follows a similar adoption in North Carolina and signals growing demand for robotic solutions in the 2.5 million annual peripheral endovascular procedures in the U.S. The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for these procedures and recently gained approval for marketing in Israel.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Microbot Medical is now worth
$ 14.85
Resulting in a loss of
$ 85.15 (85.15%)
Note: Past profits do not guarantee future returns.
